摘要
目的探讨他克莫司联合利妥昔单抗治疗系统性红斑狼疮(SLE)的临床疗效及对患者单核细胞趋化蛋白-1(MCP-1)水平和免疫相关指标的影响。方法选取医院2019年4月至2020年10月收治的SLE患者160例,按随机数字表法分为对照组和联合组,各80例。两组患者均予对症治疗,并口服他克莫司胶囊,联合组患者加予利妥昔单抗注射液静脉滴注。结果联合组总有效率为91.25%,显著高于对照组的72.50%(P<0.05)。与对照组比较,联合组患者治疗后的血清免疫球蛋白(Ig)A,IgG,IgM,MCP-1水平均显著降低,T淋巴细胞亚群中CD_(4)^(+)水平、CD_(4)^(+)/CD_(8)^(+)均显著升高(P<0.05)。两组患者的并发症发生率及不良反应发生率均无显著差异(P>0.05)。结论他克莫司联合利妥昔单抗治疗SLE,能有效改善临床症状,提高患者免疫功能,降低MCP-1水平。
Objective To investigate the clinical efficacy of tacrolimus combined with rituximab in the treatment of systemic lupus erythematosus(SLE)and its effect on the level of monocyte chemoattractant protein-1(MCP-1)and immune-related indicators.Methods A total of 160 patients with SLE admitted to the hospital from April 2019 to October 2020 were selected and divided into the control group and the combined group according to the random number table method,with 80 cases in each group.The patients in the two groups were treated with symptomatic treatment and Tacrolimus Capsules,on this basis,the patients in the combined group were given an intravenous drip of Rituximab Injection.Results The total effective rate in the combined group was 91.25%,which was significantly higher than 72.50% in the control group(P<0.05).Compared with those in the control group,the levels of serum immunoglobulin(Ig)A,IgG,IgM and MCP-1 were significantly lower,the CD_(4)^(+)level,CD_(4)^(+)/CD_(8)^(+)in T lymphocyte subsets were significantly higher in the combined group after treatment(P<0.05).There was no significant difference in the total incidence of complications and adverse drug reactions between the two groups(P>0.05).Conclusion Tacrolimus combined with rituximab in the treatment of SLE can effectively improve clinical symptoms and immune function,and it also can reduce MCP-1 level.
作者
黄美琼
刘赞
陈维飞
邢诒喜
梁金
刘军麟
裴华
李志路
HUANG Meiqiong;LIU Zan;CHEN Weifei;XING Yixi;LIANG Jin;LIU Junlin;PEI Hua;LI Zhilu(Department of Rheumatology,The Second Affiliated Hospital of Hainan Medical College,Haikou,Hainan,China 570311)
出处
《中国药业》
CAS
2022年第16期83-85,共3页
China Pharmaceuticals
基金
海南省重点研发计划项目[ZDYF2019166]。
